No Picture
News

Phoenix Molecular Designs Announces Collaboration To Develop Diagnostic for Triple-Negative Breast Cancer

-Diagnostic can detect activated RSK2, a prime target in TNBC, in breast cancer patients-

VANCOUVER, British Columbia and SAN DIEGO, Jan. 16, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing… […]

No Picture
News

GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification

AmMag SA magnetic purification system first to offer high throughput of large samples, accelerating early stage drug development

SAN DIEGO, Jan. 14, 2019 /PRNewswire/ — GenScript®, the world’s leading gene synthesis provider, announced today at PepT… […]

No Picture
News

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

– Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation- Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with Data Projected in Second Half of 2019

SAN DIEGO,… […]

No Picture
News

Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke

– itMSCs were safe and well tolerated in the study — Results of the study are supportive of advancing clinical program — Plans are underway to conduct Phase IIb trial following consultation with the FDA –

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Ste… […]

No Picture
News

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and n… […]

No Picture
News

Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

LA JOLLA, Calif., Jan. 7, 2019 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as … […]